Latest Vancomycin Stories
SEOUL, South Korea, May 10 /PRNewswire/ -- CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe. CG400549 is a potential first-in-class antibiotic candidate targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme in generating bacterial membrane) as it has novel chemical structure which has never been used as an...
SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection (CDI). The data, presented by Stuart Johnson, M.D.
EXTON, Pa., April 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Deutsche Bank 35th Annual Healthcare Conference at 1:30 P.M. ET on Tuesday, May 4, 2010.
EXTON, Pa., April 27 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze(TM) (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema (HAE).
SAN DIEGO, April 22 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc.
EXTON, Pa., April 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2010 are expected to be released on Wednesday, April 28, 2010 before the open of the U.S.
Researchers identify the specific mechanism that triggers resistance to vancomycin.
NEW YORK, March 22 /PRNewswire/ -- Recent clinical tests demonstrate that antimicrobial copper is effective in significantly reducing the bacterial load in intensive care unit (ICU) patient rooms and on many individual objects in those rooms. Results from a U.S.
FLORENCE, Italy and EXTON, Pa., March 19 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of two abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.
WALTHAM, Mass., March 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists' prescribing decisions in the treatment of complicated skin and skin structure infections (cSSSIs).
Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...
Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...